Products
Preparation registered in Ukraine
Serhienko A., Segin V., Serhienko V.
Livostor in lipid metabolism correction in patients with type 2 diabetes with coronary heart disease. Basic and clinical endocrinology: problems, achievements and prospects
In the study effectiveness of the drug Livostor (produced by “Kyiv Vitamin Factory”) in treatment of disorders of lipid metabolism in patients with type 2 diabetes and coronary heart disease (CHD) was evaluated. It was concluded that the drug Livostor is highly effective in treatment of patients with type 2 diabetes and IBS with disorders of lipid metabolism. Application of Livostor in a dose of 20 mg daily for 12 weeks helps to reduce total cholesterol by 28.2%, LDL-C — by 34.1%, TG — by 14.1% and to achieve target levels of LDL-C in 81% of patients. These studies allow us to recommend Livostor for patients with type 2 diabetes and coronary artery disease with disorders of lipid metabolism in a dose of 20 mg per day.
Key words: diabetes mellitus, ischemic heart disease, lipid metabolism, lipid lowering therapy, atorvastatin, Livostor.